{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T16:40:51Z","timestamp":1792341651968,"version":"4.4.0"},"posted":{"date-parts":[[2026,8,14]]},"group-title":"In Review","reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,24]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  T-cell acute lymphoblastic leukemia (T-ALL) remains a high-risk pediatric malignancy characterized by aggressive disease behavior and poor outcomes after relapse, underscoring the need for novel targeted therapies. Our group reported that aberrant activation of the MAP2K7\u2013JNK signaling axis is implicated in T-ALL pathogenesis, promoting leukemic cell survival, proliferation, and treatment resistance. In this study, we evaluated the anti-leukemic properties of the compound ASC69 in T-ALL cell lines and patient-derived xenograft cells using cell viability, apoptosis, and cell cycle analyses. Pathway inhibition was examined by immunoblotting. ASC69 exhibited dose-dependent cytotoxicity across multiple T-ALL cell lines, with IC\u2085\u2080 values in the low nanomolar range, while showing reduced cytotoxicity against normal human bone marrow cells. Genetic ablation of the MAP2K7 gene in Jurkat cells significantly increased the ASC69 IC\n                  <sub>50<\/sub>\n                  , supporting MAP2K7 as the primary functional target. Mechanistically, ASC69 induced G2\/M cell-cycle arrest and apoptosis, as determined by Annexin V staining and cleavage of PARP and Caspase-3.\n                  <italic>In vitro<\/italic>\n                  kinase assays demonstrated direct inhibition of MAP2K7 enzymatic activity across multiple activation conformations, including wild-type, an active phosphomimetic mutant, and an active phosphomimetic mutant with a 75-deletion in the N-terminus. Consistent with on-target pathway engagement, ASC69 inhibited both basal and stress-induced phosphorylation of JNK and ATF2 in T-ALL cell lines. Importantly, ASC69 demonstrated cytotoxic activity in T-ALL patient-derived xenograft cells and synergized with standard-of-care T-ALL drugs. Collectively, these findings establish ASC69 as a promising MAP2K7-targeted therapeutic candidate and support preclinical studies in T-ALL models.\n                <\/p>","DOI":"10.21203\/rs.3.rs-10474945\/v1","type":"posted-content","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:20:36Z","timestamp":1786710036000},"source":"Crossref","is-referenced-by-count":0,"title":["Off-Target MAP2K7 Inhibition Drives the Antileukemic Activity of the PD-1\/PD-L1 inhibitor ACS-69 in Pediatric T-ALL"],"prefix":"10.21203","author":[{"given":"Eric J.","family":"Malmberg","sequence":"first","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory Seth","family":"Bridges","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarsi","family":"Shai","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Beatty","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Texas Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Puppi","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl A.","family":"Scheidt","sequence":"additional","affiliation":[{"name":"Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Daniel","family":"Lacorazza","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"590033","DOI":"10.3389\/fonc.2020.590033","article-title":"Genetic Predisposition to Solid Pediatric Cancers","volume":"10","author":"Capasso M","year":"2020","unstructured":"Capasso M, Montella A, Tirelli M, Maiorino T, Cantalupo S, Iolascon A (2020) Genetic Predisposition to Solid Pediatric Cancers. Front Oncol 10:590033. https:\/\/doi.org\/10.3389\/fonc.2020.590033","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui C-H","year":"2008","unstructured":"Pui C-H, Robison LL, Look AT (2008) Acute lymphoblastic leukaemia. Lancet 371:1030\u20131043. https:\/\/doi.org\/10.1016\/S0140-6736(08)60457-2","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update","volume":"29","author":"Pui C-H","year":"2011","unstructured":"Pui C-H, Carroll WL, Meshinchi S, Arceci RJ, Biology (2011) Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update. J Clin Oncol 29:551\u2013565. https:\/\/doi.org\/10.1200\/JCO.2010.30.7405","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of Acute Lymphoblastic Leukemia","volume":"354","author":"Pui C-H","year":"2006","unstructured":"Pui C-H, Evans WE (2006) Treatment of Acute Lymphoblastic Leukemia. N Engl J Med 354:166\u2013178. https:\/\/doi.org\/10.1056\/NEJMra052603","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972","author":"Hunger SP","year":"2015","unstructured":"Hunger SP, Mullighan CG (2015) Acute Lymphoblastic Leukemia in Children. Longo DL, editor. N Engl J Med. ;373:1541\u201352. https:\/\/doi.org\/10.1056\/NEJMra1400972"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba H","year":"2020","unstructured":"Inaba H, Mullighan CG (2020) Pediatric acute lymphoblastic leukemia. Haematologica 105:2524\u20132539. https:\/\/doi.org\/10.3324\/haematol.2020.247031","journal-title":"Haematologica"},{"key":"ref7","author":"Raetz EA","unstructured":"Raetz EA, Teachey DT T-cell acute lymphoblastic leukemia"},{"key":"ref8","article-title":"Treatment of Acute Lymphoblastic Leukemia","author":"Waring R","year":"2006","unstructured":"Waring R (2006) Treatment of Acute Lymphoblastic Leukemia. N Engl J Med","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/leu.2014.142","article-title":"A revised definition for cure of childhood acute lymphoblastic leukemia","volume":"28","author":"Pui CH","year":"2014","unstructured":"Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP et al (2014) A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 28:2336\u20132343. https:\/\/doi.org\/10.1038\/leu.2014.142","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study","volume":"28","author":"Ko RH","year":"2010","unstructured":"Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E et al (2010) Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study. J Clin Oncol 28:648\u2013654. https:\/\/doi.org\/10.1200\/JCO.2009.22.2950","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"38","author":"Rheingold SR","year":"2024","unstructured":"Rheingold SR, Bhojwani D, Ji L, Xu X, Devidas M, Kairalla JA et al (2024) Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia 38:2382\u20132394. https:\/\/doi.org\/10.1038\/s41375-024-02395-4","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/leu.2016.339","article-title":"Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway","volume":"31","author":"Shen Y","year":"2017","unstructured":"Shen Y, Park CS, Suppipat K, Mistretta T-A, Puppi M, Horton TM et al (2017) Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia 31:1314\u20131324. https:\/\/doi.org\/10.1038\/leu.2016.339","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/ni.1730","article-title":"Transcription factor ELF4 controls the proliferation and homing of CD8\u2009+\u2009T cells via the Kr\u00fcppel-like factors KLF4 and KLF2","volume":"10","author":"Yamada T","year":"2009","unstructured":"Yamada T, Park CS, Mamonkin M, Lacorazza HD (2009) Transcription factor ELF4 controls the proliferation and homing of CD8\u2009+\u2009T cells via the Kr\u00fcppel-like factors KLF4 and KLF2. Nat Immunol 10:618\u2013626. https:\/\/doi.org\/10.1038\/ni.1730","journal-title":"Nat Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/1476-4598-13-175","article-title":"miR-2909-mediated regulation of KLF4: a novel molecular mechanism for differentiating between B-cell and T-cell pediatric acute lymphoblastic leukemias","volume":"13","author":"Malik D","year":"2014","unstructured":"Malik D, Kaul D, Chauhan N, Marwaha RK (2014) miR-2909-mediated regulation of KLF4: a novel molecular mechanism for differentiating between B-cell and T-cell pediatric acute lymphoblastic leukemias. Mol Cancer 13:175. https:\/\/doi.org\/10.1186\/1476-4598-13-175","journal-title":"Mol Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.exphem.2017.04.009","article-title":"Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia","volume":"53","author":"Shen Y","year":"2017","unstructured":"Shen Y, Chen TJ, Lacorazza HD (2017) Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia. Exp Hematol 53:16\u201325. https:\/\/doi.org\/10.1016\/j.exphem.2017.04.009","journal-title":"Exp Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1486756","DOI":"10.3389\/fonc.2024.1486756","article-title":"Pharmacological inhibition of the MAP2K7 kinase in human disease","volume":"14","author":"Lacorazza HD","year":"2024","unstructured":"Lacorazza HD (2024) Pharmacological inhibition of the MAP2K7 kinase in human disease. Front Oncol 14:1486756. https:\/\/doi.org\/10.3389\/fonc.2024.1486756","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"73366","DOI":"10.18632\/oncotarget.20672","article-title":"KLF4 represses MAP2K7 signaling in T-ALL","volume":"8","author":"Lacorazza HD","year":"2017","unstructured":"Lacorazza HD (2017) KLF4 represses MAP2K7 signaling in T-ALL. Oncotarget 8:73366\u201373367. https:\/\/doi.org\/10.18632\/oncotarget.20672","journal-title":"Oncotarget"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1084\/jem.194.6.757","article-title":"The Stress Kinase Mitogen-Activated Protein Kinase Kinase (Mkk)7 Is a Negative Regulator of Antigen Receptor and Growth Factor Receptor\u2013Induced Proliferation in Hematopoietic Cells","volume":"194","author":"Sasaki T","year":"2001","unstructured":"Sasaki T, Wada T, Kishimoto H, Irie-Sasaki J, Matsumoto G, Goto T et al (2001) The Stress Kinase Mitogen-Activated Protein Kinase Kinase (Mkk)7 Is a Negative Regulator of Antigen Receptor and Growth Factor Receptor\u2013Induced Proliferation in Hematopoietic Cells. J Exp Med 194:757\u2013768. https:\/\/doi.org\/10.1084\/jem.194.6.757","journal-title":"J Exp Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"127546","DOI":"10.1016\/j.bmcl.2020.127546","article-title":"Structural basis for producing selective MAP2K7 inhibitors","volume":"30","author":"Murakawa Y","year":"2020","unstructured":"Murakawa Y, Valter S, Barr H, London N, Kinoshita T (2020) Structural basis for producing selective MAP2K7 inhibitors. Bioorg Med Chem Lett 30:127546. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127546","journal-title":"Bioorg Med Chem Lett"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e2903","DOI":"10.1038\/cddis.2017.295","article-title":"The role of MAP2 kinases and p38 kinase in acute murine liver injury models","volume":"8","author":"Zhang J","year":"2017","unstructured":"Zhang J, Min RWM, Le K, Zhou S, Aghajan M, Than TA et al (2017) The role of MAP2 kinases and p38 kinase in acute murine liver injury models. Cell Death Dis 8:e2903\u2013e2903. https:\/\/doi.org\/10.1038\/cddis.2017.295","journal-title":"Cell Death Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"32662","DOI":"10.1074\/jbc.M304229200","article-title":"A Docking Site in MKK4 Mediates High Affinity Binding to JNK MAPKs and Competes with Similar Docking Sites in JNK Substrates","volume":"278","author":"Ho DT","year":"2003","unstructured":"Ho DT, Bardwell AJ, Abdollahi M, Bardwell L (2003) A Docking Site in MKK4 Mediates High Affinity Binding to JNK MAPKs and Competes with Similar Docking Sites in JNK Substrates. J Biol Chem 278:32662\u201332672. https:\/\/doi.org\/10.1074\/jbc.M304229200","journal-title":"J Biol Chem"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"73366","DOI":"10.18632\/oncotarget.20672","article-title":"KLF4 represses MAP2K7 signaling in T-ALL","volume":"8","author":"Lacorazza HD","year":"2017","unstructured":"Lacorazza HD (2017) KLF4 represses MAP2K7 signaling in T-ALL. Oncotarget 8:73366\u201373367. https:\/\/doi.org\/10.18632\/oncotarget.20672","journal-title":"Oncotarget"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.18632\/oncotarget.28040","article-title":"Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia","volume":"12","author":"Chen TJ","year":"2021","unstructured":"Chen TJ, Du W, Junco JJ, Bridges CS, Shen Y, Puppi M et al (2021) Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia. Oncotarget 12:1787\u20131801. https:\/\/doi.org\/10.18632\/oncotarget.28040","journal-title":"Oncotarget"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"215803","DOI":"10.1016\/j.canlet.2022.215803","article-title":"The EEF1AKMT3\/MAP2K7\/TP53 axis suppresses tumor invasiveness and metastasis in gastric cancer","volume":"544","author":"Hong YH","year":"2022","unstructured":"Hong YH, Aziz N, Park JG, Lee D, Kim JK, Kim SA et al (2022) The EEF1AKMT3\/MAP2K7\/TP53 axis suppresses tumor invasiveness and metastasis in gastric cancer. Cancer Lett 544:215803. https:\/\/doi.org\/10.1016\/j.canlet.2022.215803","journal-title":"Cancer Lett"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"16687","DOI":"10.1021\/acs.jmedchem.1c01422","article-title":"Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1\/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage","volume":"64","author":"Song Z","year":"2021","unstructured":"Song Z, Liu B, Peng X, Gu W, Sun Y, Xing L et al (2021) Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1\/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage. J Med Chem 64:16687\u201316702. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01422","journal-title":"J Med Chem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.chembiol.2020.07.014","article-title":"Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities","volume":"27","author":"Schr\u00f6der M","year":"2020","unstructured":"Schr\u00f6der M, Tan L, Wang J, Liang Y, Gray NS, Knapp S et al (2020) Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities. Cell Chem Biol 27:1285\u20131295e4. https:\/\/doi.org\/10.1016\/j.chembiol.2020.07.014","journal-title":"Cell Chem Biol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2210\/pdb6yg5\/pdb","article-title":"Crystal structure of MKK7 (MAP2K7) in complex with AC69","author":"Chaikuad A","year":"2020","unstructured":"Chaikuad A, Knapp S (2020) Crystal structure of MKK7 (MAP2K7) in complex with AC69. \/https:\/\/doi.org\/10.2210\/pdb6yg5\/pdb. Structural Genomics Consortium (SGC)https:\/\/doi.org"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/bloodadvances.2022008548","article-title":"Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia","volume":"7","author":"Bridges CS","year":"2023","unstructured":"Bridges CS, Chen TJ, Puppi M, Rabin KR, Lacorazza HD (2023) Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia. Blood Adv 7:422\u2013435. https:\/\/doi.org\/10.1182\/bloodadvances.2022008548","journal-title":"Blood Adv"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng S","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z et al (2022) SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. Genomics Proteom Bioinf 20:587\u2013596. https:\/\/doi.org\/10.1016\/j.gpb.2022.01.004","journal-title":"Genomics Proteom Bioinf"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"13169","DOI":"10.1074\/jbc.M601010200","article-title":"Interacting JNK-docking Sites in MKK7 Promote Binding and Activation of JNK Mitogen-activated Protein Kinases","volume":"281","author":"Ho DT","year":"2006","unstructured":"Ho DT, Bardwell AJ, Grewal S, Iverson C, Bardwell L (2006) Interacting JNK-docking Sites in MKK7 Promote Binding and Activation of JNK Mitogen-activated Protein Kinases. J Biol Chem 281:13169\u201313179. https:\/\/doi.org\/10.1074\/jbc.M601010200","journal-title":"J Biol Chem"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1021\/acsmedchemlett.3c00029","article-title":"Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors","volume":"14","author":"Kim DR","year":"2023","unstructured":"Kim DR, Orr MJ, Kwong AJ, Deibler KK, Munshi HH, Bridges CS et al (2023) Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors. ACS Med Chem Lett 14:606\u2013613. https:\/\/doi.org\/10.1021\/acsmedchemlett.3c00029","journal-title":"ACS Med Chem Lett"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo DJ","year":"2007","unstructured":"DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT et al (2007) Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109:5136\u20135142. https:\/\/doi.org\/10.1182\/blood-2006-11-056754","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","article-title":"Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia","volume":"7","author":"Shimony S","year":"2023","unstructured":"Shimony S, Liu Y, Valtis YK, Paolino JD, Place AE, Brunner AM et al (2023) Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia. Blood Adv 7:1092\u20131102. https:\/\/doi.org\/10.1182\/bloodadvances.2022008280","journal-title":"Blood Adv"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-Molecule Inhibitors of the Programmed Cell Death-1\/Programmed Death-Ligand 1 (PD-1\/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1","volume":"60","author":"Guzik K","year":"2017","unstructured":"Guzik K, Zak KM, Grudnik P, Magiera K, Musielak B, T\u00f6rner R et al (2017) Small-Molecule Inhibitors of the Programmed Cell Death-1\/Programmed Death-Ligand 1 (PD-1\/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J Med Chem 60:5857\u20135867. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00293","journal-title":"J Med Chem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1038\/onc.2008.301","article-title":"JNK signaling in apoptosis","volume":"27","author":"Dhanasekaran DN","year":"2008","unstructured":"Dhanasekaran DN, Reddy EP (2008) JNK signaling in apoptosis. Oncogene 27:6245\u20136251. https:\/\/doi.org\/10.1038\/onc.2008.301","journal-title":"Oncogene"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1126\/science.288.5467.870","article-title":"Requirement of JNK for Stress- Induced Activation of the Cytochrome c-Mediated Death Pathway","volume":"288","author":"Tournier C","year":"2000","unstructured":"Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al (2000) Requirement of JNK for Stress- Induced Activation of the Cytochrome c-Mediated Death Pathway. Science 288:870\u2013874. https:\/\/doi.org\/10.1126\/science.288.5467.870","journal-title":"Science"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1385\/CBB:43:3:451","article-title":"Mitogen-Activated Protein Kinases in Cell-Cycle Control","volume":"43","author":"MacCorkle RA","year":"2005","unstructured":"MacCorkle RA, Tan T-H (2005) Mitogen-Activated Protein Kinases in Cell-Cycle Control. Cell Biochem Biophys 43:451\u2013462. https:\/\/doi.org\/10.1385\/CBB:43:3:451","journal-title":"Cell Biochem Biophys"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/MCB.19.2.1569","article-title":"The MKK7 Gene Encodes a Group of c-Jun NH2 -Terminal Kinase Kinases","volume":"19","author":"Tournier C","year":"1999","unstructured":"Tournier C, Whitmarsh AJ, Cavanagh J, Barrett T, Davis RJ (1999) The MKK7 Gene Encodes a Group of c-Jun NH2 -Terminal Kinase Kinases. Mol Cell Biol 19:1569\u20131581. https:\/\/doi.org\/10.1128\/MCB.19.2.1569","journal-title":"Mol Cell Biol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1038\/s41467-020-19582-3","article-title":"Co-regulation of the transcription controlling ATF2 phosphoswitch by JNK and p38","volume":"11","author":"Kirsch K","year":"2020","unstructured":"Kirsch K, Zeke A, T\u0151ke O, Sok P, Sethi A, Seb\u0151 A et al (2020) Co-regulation of the transcription controlling ATF2 phosphoswitch by JNK and p38. Nat Commun 11:5769. https:\/\/doi.org\/10.1038\/s41467-020-19582-3","journal-title":"Nat Commun"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"27458","DOI":"10.1074\/jbc.M401009200","article-title":"Human Vaccinia-related Kinase 1 (VRK1) Activates the ATF2 Transcriptional Activity by Novel Phosphorylation on Thr-73 and Ser-62 and Cooperates with JNK","volume":"279","author":"Sevilla A","year":"2004","unstructured":"Sevilla A, Santos CR, Vega FM, Lazo PA (2004) Human Vaccinia-related Kinase 1 (VRK1) Activates the ATF2 Transcriptional Activity by Novel Phosphorylation on Thr-73 and Ser-62 and Cooperates with JNK. J Biol Chem 279:27458\u201327465. https:\/\/doi.org\/10.1074\/jbc.M401009200","journal-title":"J Biol Chem"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.3390\/ijms24087201","article-title":"An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia","volume":"24","author":"Patel J","year":"2023","unstructured":"Patel J, Gao X, Wang H (2023) An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci 24:7201. https:\/\/doi.org\/10.3390\/ijms24087201","journal-title":"Int J Mol Sci"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10474945\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10474945\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T15:53:46Z","timestamp":1792338826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10474945\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":41,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10474945\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,8,14]]},"subtype":"preprint"}}